Ovarian CancerPhase 3VELIANCT02470585
Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase 3 study testing Veliparib, Paclitaxel and Carboplatin in people with Ovarian Cancer and Ovarian Neoplasm, run by AbbVie at 210 sites in 11 countries.
Trial summary
The primary objective of the study was to evaluate whether progression-free survival (PFS) was prolonged with the addition of veliparib to standard platinum-based chemotherapy (carboplatin/paclitaxel [C/P]) and continued as maintenance therapy compared with chemotherapy alone. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Ovarian Cancer, Ovarian Neoplasm
- What is being tested?
- Veliparib, Paclitaxel and Carboplatin
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 1,140 participants
- Where
- 210 sitesin 11 countries
- Study dates
- 14 Jul 2015to 5 Oct 2023
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Histologic diagnosis of International Federation of Gynecology and Obstetrics (FIGO) Stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, with the appropriate tissue available for histologic evaluation.
- High-grade serous adenocarcinoma
- Willing to undergo testing for gBRCA.
- Adequate hematologic, renal, and hepatic function.
- Neuropathy (sensory and motor) less than or equal to Grade 1.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
Show all 9Show fewer
- Participants who undergo primary cytoreductive surgery must be entered between 1 and 12 weeks after surgery. Participants undergoing interval surgery must have a tumor sample confirming the histological diagnosis prior to enrollment.
- Participants with measurable disease or non-measurable disease are eligible. Participants may or may not have cancer-related symptoms.
- Participant has one of the following available for pharmacodynamic analyses including somatic BRCA testing: Archived diagnostic formalin-fixed paraffin embedded (FFPE) tumor tissue; or tumor tissue biopsy collected prior to Cycle 1 Day 1.
Who cannot join
- Endometrioid adenocarcinoma, carcinosarcoma, undifferentiated carcinoma, mixed epithelial adenocarcinoma, adenocarcinoma not otherwise specified, mucinous adenocarcinoma, clear cell adenocarcinoma, low-grade serous adenocarcinoma, or malignant Brenner's tumor.
- Participants with synchronous primary endometrial cancer, or a past history of endometrial cancer unless all of the following conditions are met: endometrial cancer stage not greater than IA, no vascular or lymphatic invasion, no poorly differentiated subtypes including serous, clear cell, or other FIGO grade 3 lesions.
- Participants with any evidence of other invasive malignancy being present within the last 3 years (with the exception of non-melanoma skin cancer). Participants are also excluded if their previous cancer treatment contraindicates this protocol's therapy.
- Received prior radiotherapy to any portion of the abdominal cavity or pelvis.
- Received prior chemotherapy for any abdominal or pelvic tumor.
- Clinically significant uncontrolled condition(s).
- Known history of allergic reaction to Cremophor-paclitaxel, carboplatin, Azo-Colourant Tartrazine (also known as FD\&C Yellow 5 or E102), Azo-Colourant Orange Yellow-S (also known as FD\&C Yellow 6 or E110) or known contraindications to any study supplied drug.
- History or evidence upon physical examination of central nervous system (CNS) disease, including primary brain tumor, any brain metastases, or history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) within 6 months of Cycle 1 Day 1.
Trial locations and contacts
210 sites in 11 countries.
210 sites in 11 countries
United States135 sites
Abington Memorial Hospital /ID# 138086
Abington, Pennsylvania, 19001
Women's Cancer Care Associates /ID# 138234
Albany, New York, 12208
University of New Mexico /ID# 144220
Albuquerque, New Mexico, 87102
SW Gynecologic Oncology Assoc /ID# 147097
Albuquerque, New Mexico, 87106
McFarland Clinic, PC /ID# 139455
Ames, Iowa, 50010
Alaska Womens Cancer Care /ID# 138231
Anchorage, Alaska, 99508-4684
Hope Womens Cancer Centers /ID# 139614
Asheville, North Carolina, 28816
Georgia Regents University /ID# 138085
Augusta, Georgia, 30912
Kaiser Permanente, Waterpark III Institute for Health Research /ID# 139499
Aurora, Colorado, 80014
Univ of Colorado Cancer Center /ID# 138016
Aurora, Colorado, 80045
Texas Oncology - Austin Central /ID# 143817
Austin, Texas, 78731
Texas Oncology - South Austin /ID# 143818
Austin, Texas, 78745
Greater Baltimore Medical Ctr /ID# 138049
Baltimore, Maryland, 21204
Sinai Hospital of Baltimore /ID# 141306
Baltimore, Maryland, 21215
Texas Oncology - Bedford /ID# 143814
Bedford, Texas, 76022
University of Alabama at Birmingham - Main /ID# 138087
Birmingham, Alabama, 35233
SUNY Downstate Medical Center /ID# 139533
Brooklyn, New York, 11203
Roswell Park Comprehensive Cancer Center /ID# 138052
Buffalo, New York, 14263
University of Vermont Medical Center /ID# 138251
Burlington, Vermont, 05401-1473
MD Anderson Cancer Ctr at Coop /ID# 139616
Camden, New Jersey, 08103
Univ NC Chapel Hill /ID# 138547
Chapel Hill, North Carolina, 27514-4220
Medical University of South Carolina /ID# 138181
Charleston, South Carolina, 29425
Atrium Health Carolinas Medical Center /ID# 139568
Charlotte, North Carolina, 28203
Presbyterian Cancer Center /ID# 139590
Charlotte, North Carolina, 28204
University of Virginia /ID# 138088
Charlottesville, Virginia, 22908
Chattanoogas Program in Womens /ID# 139545
Chattanooga, Tennessee, 37403
Rush University Medical Center /ID# 143491
Chicago, Illinois, 60612
University of Chicago /ID# 139612
Chicago, Illinois, 60637-1443
University of Cincinnati /ID# 139619
Cincinnati, Ohio, 45267-0585
Univ Hosp Cleveland /ID# 139615
Cleveland, Ohio, 44106
Fairview Hospital /ID# 144403
Cleveland, Ohio, 44111
Cleveland Clinic Main Campus /ID# 139501
Cleveland, Ohio, 44195
Ellis Fischel Cancer Center /ID# 139571
Columbia, Missouri, 65212-1000
IACT Health /ID# 138058
Columbus, Georgia, 31904-8946
The Ohio State University - Columbus /ID# 138053
Columbus, Ohio, 43210
Columbus NCORP /ID# 139587
Columbus, Ohio, 43215
John Muir Medical Center /ID# 139618
Concord, California, 94520
Texas Oncology - Medical City Dallas /ID# 143809
Dallas, Texas, 75230
Texas Oncology - Medical City Dallas /ID# 143812
Dallas, Texas, 75230
Wayne State University /ID# 139601
Detroit, Michigan, 48201-2013
Henry Ford Health System /ID# 139536
Detroit, Michigan, 48202
Duke University Medical Center /ID# 138048
Durham, North Carolina, 27710-3000
Willamette Valley Cancer Institute /ID# 140318
Eugene, Oregon, 97401-6043
NorthShore University HealthSystem - Evanston Hospital /ID# 139451
Evanston, Illinois, 60201
Texas Oncology - Forth Worth /ID# 143811
Fort Worth, Texas, 76104-2150
HSHS St. Vincent Hospital /ID# 139453
Green Bay, Wisconsin, 54301
Hackensack Univ Med Ctr /ID# 143776
Hackensack, New Jersey, 07601
Sharma, Hinsdale, IL /ID# 140326
Hinsdale, Illinois, 60521
The Queens Medical Center /ID# 141709
Honolulu, Hawaii, 96813
Kapiolani Medical Center /ID# 140319
Honolulu, Hawaii, 96826
Houston Methodist Hospital - Scurlock Tower /ID# 138232
Houston, Texas, 77030
Memorial Hermann Hospital /ID# 138238
Houston, Texas, 77030
Tennessee Valley Gyn-Onc /ID# 139548
Huntsville, Alabama, 35805
Indiana Univ School Medicine /ID# 139610
Indianapolis, Indiana, 46202
Saint Vincent /ID# 139537
Indianapolis, Indiana, 46260
University of Iowa Hospitals and Clinics /ID# 138082
Iowa City, Iowa, 52242
St. Dominic Hospital /ID# 138241
Jackson, Mississippi, 39216
Univ Kansas Med Ctr /ID# 140322
Kansas City, Kansas, 66160
Womens Cancer Center /ID# 138062
Kettering, Ohio, 45429-1226
Ucsd /Id# 140323
La Jolla, California, 92093
Northwell Health /ID# 139572
Lake Success, New York, 11042
Womens Cancer Center of Nevada /ID# 138092
Las Vegas, Nevada, 89169
Dartmouth-Hitchcock Medical Center /ID# 139502
Lebanon, New Hampshire, 03756
Baptist Health Lexington /ID# 139542
Lexington, Kentucky, 40503
University of Kentucky Chandler Medical Center /ID# 138060
Lexington, Kentucky, 40536
University of Arkansas for Medical Sciences /ID# 138253
Little Rock, Arkansas, 72205
Long Beach Memorial Medical Ct /ID# 147526
Long Beach, California, 90806
Kaiser Permanente /ID# 141305
Los Angeles, California, 90027
University of California, Los Angeles /ID# 138179
Los Angeles, California, 90095
Norton Cancer Institute /ID# 139567
Louisville, Kentucky, 40202-3700
Hillcrest Hospital /ID# 144404
Mayfield Heights, Ohio, 44124
University of Miami /ID# 139457
Miami, Florida, 33136
Froedtert & the Medical College of Wisconsin /ID# 139449
Milwaukee, Wisconsin, 53226-3522
University of South Alabama /ID# 138091
Mobile, Alabama, 36604-3302
Skagit Valley Medical Center /ID# 139586
Mount Vernon, Washington, 98273
Hartford Healthcare /ID# 138184
New Britain, Connecticut, 6053
Yale University /ID# 138056
New Haven, Connecticut, 06510
Icahn School of Med Mt. Sinai /ID# 139617
New York, New York, 10029
Columbia University Medical Center /ID# 138252
New York, New York, 10032-3729
Memorial Sloan Kettering Cancer Center /ID# 138017
New York, New York, 10065-6007
Memorial Sloan Kettering Cancer Center /ID# 154464
New York, New York, 10065-6007
Univ Oklahoma HSC /ID# 138020
Oklahoma City, Oklahoma, 73104
Nebraska Methodist Hospital /ID# 139600
Omaha, Nebraska, 68114
Medical Oncology Care Assoc /ID# 139498
Orange, California, 92868-4304
Univ CA, Irvine Med Ctr /ID# 139613
Orange, California, 92868
Advocate Lutheran General Hosp /ID# 139489
Park Ridge, Illinois, 60068
University of Pennsylvania /ID# 140079
Philadelphia, Pennsylvania, 19104-5502
Thomas Jefferson University /ID# 138239
Philadelphia, Pennsylvania, 19107-4414
Fox Chase Cancer Center /ID# 149479
Philadelphia, Pennsylvania, 19111
University of Pittsburgh MC /ID# 138054
Pittsburgh, Pennsylvania, 15260
MMP Women's Health /ID# 139544
Portland, Maine, 04102
Kaiser Permanente, NW /ID# 138249
Portland, Oregon, 97227
Women and Infants Hospital /ID# 138083
Providence, Rhode Island, 02905
MultiCare Regional Cancer Ctr /ID# 149872
Puyallup, Washington, 93872
Reading Hospital /ID# 138057
Reading, Pennsylvania, 19611
Renown Regional Medical Center /ID# 138237
Reno, Nevada, 89502
Carilion Roanoke Memorial Hosp /ID# 139602
Roanoke, Virginia, 24014
Mayo Clinic - Rochester /ID# 139565
Rochester, Minnesota, 55905-0001
Weinberg Cancer Inst Franklin /ID# 138235
Rossville, Maryland, 21237
William Beaumont Hospital /ID# 139550
Royal Oak, Michigan, 48073-6710
UC Davis Comprehensive Cancer Center - Main /ID# 144439
Sacramento, California, 95817
Mmcorc /Id# 139534
Saint Louis Park, Minnesota, 55416
University of Utah /ID# 138250
Salt Lake City, Utah, 84112-5500
California Pacific Medical Ctr /ID# 138177
San Francisco, California, 94115
Kaiser Permanente - San Francisco /ID# 142051
San Francisco, California, 94115
Univ California, San Francisco /ID# 138178
San Francisco, California, 94143-2204
Kaiser Permanente-Santa Clara /ID# 142053
Santa Clara, California, 95051-5173
Sarasota Memorial Health Care /ID# 138180
Sarasota, Florida, 34239
Memorial Health Univ Med Ctr /ID# 138019
Savannah, Georgia, 31404
St. Joseph's/Candler /ID# 138090
Savannah, Georgia, 31405
Sanford Research/USD /ID# 139624
Sioux Falls, South Dakota, 57104-8805
Baystate Medical Center /ID# 139456
Springfield, Massachusetts, 01199
Cancer Research For the Ozarks /ID# 139538
Springfield, Missouri, 65804
Ferrell-Duncan Clinic /ID# 143484
Springfield, Missouri, 65807
Washington University-School of Medicine /ID# 138089
St Louis, Missouri, 63110
Women's Cancer Associates /ID# 140321
St. Petersburg, Florida, 33701
Stanford University School of Med /ID# 139450
Stanford, California, 94305-2200
Palo Alto Medical Foundation /ID# 139452
Sunnyvale, California, 94086
SUNY Upstate Medical University - Downtown /ID# 139513
Syracuse, New York, 13210
Multicare Institute for Research and Innovation /ID# 143485
Tacoma, Washington, 98405
Moffitt Cancer Center /ID# 138061
Tampa, Florida, 33612-9416
Montefiore Medical Center /ID# 139585
The Bronx, New York, 10461
Texas Oncology - The Woodlands /ID# 142003
The Woodlands, Texas, 77380
Arizona Oncology Associates, PC-HOPE /ID# 142002
Tucson, Arizona, 85711-2701
Arizona Oncology Associates, PC-HOPE /ID# 143805
Tucson, Arizona, 85711-2701
Arizona Oncology Associates, PC-HOPE /ID# 143806
Tucson, Arizona, 85711-2701
Arizona Oncology Associates, PC-HOPE /ID# 143808
Tucson, Arizona, 85711-2701
University of Arizona Cancer Center - North Campus /ID# 138084
Tucson, Arizona, 85719-1478
University of Arizona Cancer Center - North Campus /ID# 139495
Tucson, Arizona, 85719-1478
Oklahoma Cancer Specialists /ID# 138059
Tulsa, Oklahoma, 74146
Texas Oncology - Tyler /ID# 143810
Tyler, Texas, 75702
Kaiser Permanente Medical Ctr-Vallejo /ID# 139492
Vallejo, California, 94589-2441
Kaiser Permanente- Walnut Creek /ID# 142052
Walnut Creek, California, 94596
Wake Forest Baptist Medical Center /ID# 139588
Winston-Salem, North Carolina, 27157-0001
UMass Memorial Medical Center /ID# 139458
Worcester, Massachusetts, 01655
Japan22 sites
Hyogo Cancer Center /ID# 148327
Akashi, 673-8558
Kansai Rosai Hospital /ID# 149237
Amagasaki, 660-8511
National Hospital Organization Kyushu Cancer Center /ID# 149133
Fukuoka, Fukuoka, 811-1395
The Jikei Univ. Kashiwa Hosp. /ID# 149238
Kashiwa-shi, 277-0004
St. Marianna Univ Hospital /ID# 149327
Kawasaki, 216-8511
The Cancer Institute Hosp JFCR /ID# 148436
Koto-ku, Tokyo, 135-8550
Kumamoto University Hospital /ID# 154169
Kumamoto, Kumamoto, 860-8556
NHO Kure Medical Center and Ch /ID# 148569
Kure, 737-0023
Kurume University Hospital /ID# 148697
Kurume-shi, Fukuoka, 830-0011
Shikoku Cancer Center /ID# 148382
Matsuyama, 791-0280
Aichi Cancer Center Hospital /ID# 148398
Nagoya, Aichi-ken, 464-8681
Niigata University Medical & Dental Hospital /ID# 149488
Niigata, Niigata, 951-8520
Osaka International Cancer Institute /ID# 150778
Osaka, 541-8567
Kindai University Hospital /ID# 154947
Ōsaka-sayama, Osaka, 5898511
Hokkaido Cancer Center /ID# 148570
Sapporo, 003-0804
Tohoku University Hospital /ID# 149818
Sendai, Miyagi, 980-8574
Keio University Hospital /ID# 148326
Shinjuku-ku, Tokyo, 160-8582
Iwate Medical University Hospital /ID# 147721
Shiwa-gun, Iwate, 028-3695
Shizuoka Cancer Center /ID# 147723
Sunto-gun, Shizuoka, 411-8777
The Jikei University Hospital /ID# 148691
Tokyo, 105-8461
Mie University Hospital /ID# 149169
Tsu, Mie-ken, 514-8507
Yamagata University Hospital /ID# 153646
Yamagata, Yamagata, 990-9585
Australia19 sites
Royal Adelaide Hospital /ID# 150071
Adelaide, South Australia, 5000
Monash Health /ID# 145297
Clayton, Victoria, 3168
Coffs Harbour Health Campus /ID# 145132
Coffs Harbour, New South Wales, 2450
The Townsville Hospital /ID# 149163
Douglas, Queensland, 4814
Gosford Hospital /ID# 145299
Gosford, New South Wales, 2250
Royal Brisbane and Women's Hospital /ID# 145135
Herston, Queensland, 4029
St George Hospital /ID# 145138
Kogarah, New South Wales, 2217
Newcastle Private Hospital /ID# 145834
Lambton Heights, New South Wales, 2305
Cabrini Health /ID# 145142
Malvern, Victoria, 3144
Sir Charles Gairdner Hospital /ID# 145140
Nedlands, Western Australia, 6009
Royal Womens Hospital /ID# 145136
Parkville, Victoria, 3052
The Prince of Wales Hospital /ID# 145134
Randwick, New South Wales, 2031
Icon Cancer Centre /ID# 148208
South Brisbane, Queensland, 4101
Mater Misericordiae Limited /ID# 145682
South Brisbane, Queensland, 4101
Northern Cancer Institute /ID# 145681
St Leonards, New South Wales, 2065
St. John of God Subiaco Hosp /ID# 147742
Subiaco, Western Australia, 6008
Calvary Mater Newcastle /ID# 145139
Waratah, New South Wales, 2298
Westmead Hospital /ID# 145137
Westmead, New South Wales, 2145
Southern Medical Day Care Ctr /ID# 145133
Wollongong, New South Wales, 2500
Spain7 sites
Hospital Univ Vall d'Hebron /ID# 137297
Barcelona, 08035
Hospital Clinic de Barcelona /ID# 137300
Barcelona, 08036
Hospital Duran i Reynals /ID# 137298
L'Hospitalet de Llobregat, Barcelona, 08907
Hospital Clin Univ San Carlos /ID# 137402
Madrid, 28040
Hosp Univ 12 de Octubre /ID# 137299
Madrid, 28041
Hosp Univ Madrid Sanchinarro /ID# 137414
Madrid, 28050
Fundacion Inst Valenciano Onc /ID# 137403
Valencia, 46009
Israel6 sites
Rambam Health Care Campus /ID# 137434
Haifa, 3109601
The Lady Davis Carmel MC /ID# 137537
Haifa, 3436212
Shaare Zedek Medical Center /ID# 137435
Jerusalem, 91031
Meir Medical Center /ID# 139397
Kfar Saba, 4428164
Sheba Medical Center /ID# 137436
Ramat Gan, 5262100
Kaplan Medical Center /ID# 137536
Rehovot, 76100
South Korea6 sites
National Cancer Center /ID# 139404
Goyang, Gyeonggido, 10408
Gangnam Severance Hospital /ID# 136835
Seoul, Seoul Teugbyeolsi, 06273
Samsung Medical Center /ID# 136834
Seoul, Seoul Teugbyeolsi, 06351
Seoul National University Hospital /ID# 136909
Seoul, 03080
Asan Medical Center /ID# 136836
Seoul, 05505
Korea University Anam Hospital /ID# 136908
성북구, Gyeonggido, 02841
United Kingdom6 sites
Ninewells Hospital /ID# 137967
Dundee, DD1 9SY
Beatson west of scotland cancer center /ID# 137965
Glasgow, Scotland, G12 0YN
James Paget University Hosp /ID# 137970
Great Yarmouth, NR31 6LA
Imanova Limited, Hammersmith Hospital /ID# 137966
London, W12 0HS
Norfolk and Norwich Univ Hosp /ID# 137969
Norwich, Norfolk, NR4 7UY
Oxford Univ Hosp NHS Trust /ID# 137973
Oxford, OX3 7LE
Brazil5 sites
Hospital de Cancer de Barretos /ID# 137121
Barretos, São Paulo, 14784-400
Hc Ufmg /Id# 137156
Belo Horizonte, Minas Gerais, 30130-100
Hospital Sao Lucas da PUCRS /ID# 137157
Porto Alegre, Rio Grande do Sul, 90610-000
Instituto Nacional de Câncer José de Alencar Gomes da Silva (INCA) /ID# 137155
Rio de Janeiro, 20231-050
Centro de Referencia da Saude da Mulher - Hospital Perola Byington /ID# 137120
São Paulo, São Paulo, 01317-000
Denmark2 sites
Regionshospitalet Herning /ID# 137260
Herning, 7400
Vejle Sygehus /ID# 137262
Vejle, Region Syddanmark, 7100
About this study
Official title: A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP Inhibitor) in Subjects With Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
The primary objective of the study was to evaluate whether progression-free survival (PFS) was prolonged with the addition of veliparib to standard platinum-based chemotherapy (carboplatin/paclitaxel [C/P]) and continued as maintenance therapy compared with chemotherapy alone.
Read the detailed description
Participants were randomized in a 1:1:1 ratio to one of three arms. Randomization in the entire population was stratified according to the timing of surgery and residual disease status (any residual disease after primary surgery vs. no residual disease after primary surgery vs. interval surgery) and the paclitaxel schedule (weekly vs. every 3 -weeks), stage of disease (III vs. IV), geographic region (Japan vs. North America and rest of world [ROW]), and germline breast cancer susceptibility gene (BRCA) mutation status (positive versus negative or Unknown).
Cytoreductive surgery could be performed before randomization and the initiation of study treatment (primary) or after 3 cycles of study treatment (interval). The weekly or every-3-week paclitaxel schedule and the choice of primary or interval cytoreductive surgery were determined at the discretion of the investigator.
The primary objective was evaluated in the BRCA-deficient cohort, participants with homologous recombination deficiency (HRD), and the intention-to-treat (ITT) population. These populations were sequentially inclusive, with the HRD population including the BRCA-deficient population, and the ITT population including the HRD and BRCA-deficient populations. The BRCA-deficient population was defined as participants with either a germline (gBRCA) and/or tissue-based (tBRCA) deleterious or suspected deleterious mutation in BRCA1 or BRCA2 confirmed by centralized testing. The HRD population was defined as participants with HRD tumors based on HRD score or presence of a deleterious or suspected deleterious mutation in BRCA1 or BRCA2 as determined by centralized testing.
- Conditions
- Ovarian Cancer, Ovarian Neoplasm
- Being tested
- Veliparib, Paclitaxel, Carboplatin, Placebo to Veliparib
- Keywords
- Veliparib, Carboplatin, Paclitaxel, Overall Survival, ABT-888, Randomized, Poly Adenosine Diphosphate (ADP) - Ribose Polymerase (PARP), Ovarian, BRCA, VELIA
- Medical subject headings
- Ovarian Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
VeliparibDrug
Also called ABT-888
Capsules for oral administration
PaclitaxelDrug
Administered by intravenous infusion, either 80 mg/m² of body-surface area (BSA) on Days 1, 8, and 15 of each 21-day cycle (weekly dosing), or 175 mg/m² of BSA on Day 1 of each 21-day cycle (3-week dosing).
CarboplatinDrug
Administered by intravenous infusion at an area under the curve (AUC) of 6 mg/mL/min every 3 weeks.
Placebo to VeliparibOther
Capsules for oral administration
| Study group | Role | What they receive |
|---|---|---|
| Placebo + Carboplatin + Paclitaxel -> Placebo | Active comparator | Participants will receive placebo to veliparib orally twice a day in combination with carboplatin/paclitaxel for six 21-day cycles followed by placebo monotherapy continuous dosing for an additional thirty 21-day cycles. Receives: Drug: Paclitaxel; Drug: Carboplatin; Other: Placebo to Veliparib |
| Veliparib + Carboplatin + Paclitaxel -> Placebo | Experimental | Participants will receive 150 mg veliparib orally twice a day in combination with carboplatin/paclitaxel for six 21-day cycles followed by placebo monotherapy continuous dosing for an additional thirty 21-day cycles. Receives: Drug: Veliparib; Drug: Paclitaxel; Drug: Carboplatin; Other: Placebo to Veliparib |
| Veliparib + Carboplatin + Paclitaxel -> Veliparib | Experimental | Participants will receive 150 mg veliparib orally twice a day in combination with carboplatin/paclitaxel for six 21-day cycles followed by 300/400 mg veliparib monotherapy orally twice a day for an additional thirty 21-day cycles. Receives: Drug: Veliparib; Drug: Paclitaxel; Drug: Carboplatin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Progression-Free Survival (PFS) in the BRCA-deficient Population (Arm 3 vs Arm 1)
PFS was defined as the time from the date that the participant was randomized to the date the participant experienced an event of disease progression, according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1 (as determined by the investigator) or to the date of death if disease progression was not reached. If the participant did not have an event of disease progression or death prior to the analysis cut-off date, the participant's data were censored at the date of their last evaluable disease assessment. PFS was estimated using the Kaplan-Meier method. The analysis of PFS occurred when the protocol-specified number of PFS events was reached.
Progressive Disease (PD): At least a 20% increase in the size of target lesions, compared with the smallest size recorded since the treatment started, and an absolute increase of ≥ 5 mm, or unequivocal progression of existing non-target lesions or the appearance of new lesions.
Measured: From randomization until the primary analysis data cut-off date of 03 May 2019, the median duration of follow-up was 28 months.
Progression-Free Survival (PFS) in the Homologous Recombination Deficiency Cohort (Arm 3 vs Arm 1)
PFS was defined as the time from the date that the participant was randomized to the date the participant experienced an event of disease progression, according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1 (as determined by the investigator) or to the date of death if disease progression was not reached. If the participant did not have an event of disease progression or death, the participant's data were censored at the date of their last evaluable disease assessment. PFS was estimated using the Kaplan-Meier method. The primary analysis of PFS occurred when the protocol-specified number of PFS events was reached and was performed in 3 sequentially inclusive populations.
Progressive Disease (PD): At least a 20% increase in the size of target lesions, compared with the smallest size recorded since the treatment started, and an absolute increase of ≥ 5 mm, or unequivocal progression of existing non-target lesions or the appearance of new lesions.
.
Measured: From randomization until the primary analysis data cut-off date of 03 May 2019, the median duration of follow-up was 28 months.
Progression-Free Survival (PFS) in the Intention-to-treat Population (Arm 3 vs Arm 1)
PFS was defined as the time from the date that the participant was randomized to the date the participant experienced an event of disease progression, according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1 (as determined by the investigator) or to the date of death (all causes of mortality) if disease progression was not reached. If the participant did not have an event of disease progression according to RECIST criteria (as or death, the participant's data were censored at the date of their last evaluable disease assessment. PFS was estimated using the Kaplan-Meier method.
Progressive Disease (PD): At least a 20% increase in the size of target lesions, compared with the smallest size recorded since the treatment started, and an absolute increase of ≥ 5 mm, or unequivocal progression of existing non-target lesions or the appearance of new lesions.
The primary analysis of PFS occurred when the protocol-specified number of PFS events was reached.
Measured: From randomization until the primary analysis data cut-off date of 03 May 2019, the median duration of follow-up was 28 months.
Secondary outcomes (9)
Progression-Free Survival (PFS) in the BRCA-deficient Population (Arm 2 vs Arm 1)
PFS was defined as the time from the date that the participant was randomized to the date the participant experienced an event of disease progression, according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1 (as determined by the investigator) or to the date of death if disease progression was not reached. If the participant did not have an event of disease progression or death prior to the analysis cut-off date, the participant's data were censored at the date of their last evaluable disease assessment. PFS was estimated using the Kaplan-Meier method. The analysis of PFS occurred when the protocol-specified number of PFS events was reached.
Progressive Disease (PD): At least a 20% increase in the size of target lesions, compared with the smallest size recorded since the treatment started, and an absolute increase of ≥ 5 mm, or unequivocal progression of existing non-target lesions or the appearance of new lesions.
Measured: From randomization until the primary analysis data cut-off date of 03 May 2019, the median duration of follow-up was 28 months.
Progression-Free Survival (PFS) in the Homologous Recombination Deficiency Cohort (Arm 2 vs Arm 1)
PFS was defined as the time from the date that the participant was randomized to the date the participant experienced an event of disease progression, according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1 (as determined by the investigator) or to the date of death if disease progression was not reached. If the participant did not have an event of disease progression or death, the participant's data were censored at the date of their last evaluable disease assessment. PFS was estimated using the Kaplan-Meier method. The primary analysis of PFS occurred when the protocol-specified number of PFS events was reached and was performed in 3 sequentially inclusive populations.
Progressive Disease (PD): At least a 20% increase in the size of target lesions, compared with the smallest size recorded since the treatment started, and an absolute increase of ≥ 5 mm, or unequivocal progression of existing non-target lesions or the appearance of new lesions.
.
Measured: From randomization until the primary analysis data cut-off date of 03 May 2019, the median duration of follow-up was 28 months.
Progression-Free Survival (PFS) in the Intention-to-treat Population (Arm 2 vs Arm 1)
PFS was defined as the time from the date that the participant was randomized to the date the participant experienced an event of disease progression, according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1 (as determined by the investigator) or to the date of death (all causes of mortality) if disease progression was not reached. If the participant did not have an event of disease progression according to RECIST criteria (as or death, the participant's data were censored at the date of their last evaluable disease assessment. PFS was estimated using the Kaplan-Meier method.
Progressive Disease (PD): At least a 20% increase in the size of target lesions, compared with the smallest size recorded since the treatment started, and an absolute increase of ≥ 5 mm, or unequivocal progression of existing non-target lesions or the appearance of new lesions.
The primary analysis of PFS occurred when the protocol-specified number of PFS events was reached.
Measured: From randomization until the primary analysis data cut-off date of 03 May 2019, the median duration of follow-up was 28 months.
Overall Survival (OS) in the BRCA-deficient Population
OS is defined as the time from the day the participant was randomized to the date of death, and was calculated using Kaplan-Meier methods. All events of death will be included, regardless of whether the event occurs while the participant is still taking study drug, or after discontinuation of study drug. If a participant has not died, then the data will be censored at the date the participant is last known to be alive.
Measured: From the time of randomization to the end of the study, up to 98 months
Overall Survival (OS) in the Homologous Recombination Deficiency Population
OS is defined as the time from the day the participant was randomized to the date of death, and was calculated using Kaplan-Meier methods. All events of death will be included, regardless of whether the event occurs while the participant is still taking study drug, or after discontinuation of study drug. If a participant has not died, then the data will be censored at the date the participant is last known to be alive.
Measured: From the time of randomization to the end of the study, up to 98 months
Overall Survival (OS) in the Whole Population
OS is defined as the time from the day the participant was randomized to the date of death, and was calculated using Kaplan-Meier methods. All events of death will be included, regardless of whether the event occurs while the participant is still taking study drug, or after discontinuation of study drug. If a participant has not died, then the data will be censored at the date the participant is last known to be alive.
Measured: From the time of randomization to the end of the study, up to 98 months
Change From Baseline in Disease Related Symptom (DRS) Score in the BRCA-mutation Population
The Disease Related Symptom score is a subset of the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy Ovarian Symptom Index-18 (NFOSI-18), which evaluates nine symptoms related to ovarian cancer. The NFOSI-18 DRS score ranges from 0 to 36, with higher scores indicating a lower burden of symptoms and a score of 0 being severely symptomatic. A 3-point difference was defined as clinically meaningful. A positive change from Baseline indicates improvement.
Change from Baseline was calculated using a used a mixed-model for repeated measures (MMRM) with treatment, stratification factors of residual disease and stage of disease, time point and treatment-by-time point interaction as fixed effect factors, and Baseline DRS score as a covariate.
DRS was not included in the fixed-sequence testing procedure.
Measured: Baseline and Day 1 of Cycles 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, and 35
Change From Baseline in Disease Related Symptom (DRS) Score in the HRD Population
The Disease Related Symptom score is a subset of the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy Ovarian Symptom Index-18 (NFOSI-18), which evaluates nine symptoms related to ovarian cancer. The NFOSI-18 DRS score ranges from 0 to 36, with higher scores indicating a lower burden of symptoms and a score of 0 being severely symptomatic. A 3-point difference was defined as clinically meaningful. A positive change from Baseline indicates improvement.
Change from Baseline was calculated using a used a mixed-model for repeated measures (MMRM) with treatment, stratification factors of residual disease and stage of disease, time point and treatment-by-time point interaction as fixed effect factors, and Baseline DRS score as a covariate.
DRS was not included in the fixed-sequence testing procedure.
Measured: Baseline and Day 1 of Cycles 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, and 35
Change From Baseline in Disease Related Symptom (DRS) Score in the Whole Population
The Disease Related Symptom score is a subset of the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy Ovarian Symptom Index-18 (NFOSI-18), which evaluates nine symptoms related to ovarian cancer. The NFOSI-18 DRS score ranges from 0 to 36, with higher scores indicating a lower burden of symptoms and a score of 0 being severely symptomatic. A 3-point difference was defined as clinically meaningful. A positive change from Baseline indicates improvement.
Change from Baseline was calculated using a used a mixed-model for repeated measures (MMRM) with treatment, stratification factors of residual disease, stage of disease, choice of paclitaxel dosing regimen and BRCA-deficient status, time point and treatment-by-time point interaction as fixed effect factors, and Baseline DRS score as a covariate.
DRS was not included in the fixed-sequence testing procedure.
Measured: Baseline and Day 1 of Cycles 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, and 35
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jun 2015 (estimated)
- Study start14 Jul 2015
- Primary completion3 May 2019
- Study completion5 Oct 2023
Why it stopped: Business decision not related to patient safety
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Ovarian CancerStudies of the same condition, open and under way.
- More trials run by AbbVieThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 1,140 participants (actual)
Sponsor and investigators
- Lead sponsor
- AbbVie
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Australia New Zealand Gynaecological Oncology Group
- Responsible party
- Sponsor
- Investigators
- AbbVie Inc., Study director, AbbVie
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02470585
- Sponsor's protocol ID
- M13-694
- Other IDs
- 2014-005070-11, 2014
- Acronym
- VELIA
- Status last verified
- Oct 2024
- First submitted
- 10 Jun 2015
- Last updated
- 26 Oct 2024
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- Individual data sharing
- Yes: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Publications
Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Efrat Ben-Baruch N, Werner TL, Cloven NG, Oaknin A, DiSilvestro PA, Morgan MA, Nam JH, Leath CA 3rd, Nicum S, Hagemann AR, Littell RD, Cella D, Baron-Hay S, Garcia-Donas J, Mizuno M, Bell-McGuinn K, Sullivan DM, Bach BA, Bhattacharya S, Ratajczak CK, Ansell PJ, Dinh MH, Aghajanian C, Bookman MA. Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. N Engl J Med. 2019 Dec 19;381(25):2403-2415. doi: 10.1056/NEJMoa1909707. Epub 2019 Sep 28.
PubMed 31562800Lafferty J, Secord AA, Bookman M, Coleman RL, Dinh MH, Khandelwal N, Kamalakar R, Cella D. Quality-adjusted progression-free survival analysis of veliparib and carboplatin/paclitaxel compared with chemotherapy alone in patients with newly diagnosed ovarian cancer (VELIA/GOG3005): ancillary analysis of a placebo-controlled, phase 3 randomized trial. Int J Gynecol Cancer. 2026 May;36(5):102819. doi: 10.1016/j.ijgc.2025.102819. Epub 2025 Nov 21.
PubMed 41565553Swisher EM, Aghajanian C, O'Malley DM, Fleming GF, Kaufmann SH, Levine DA, Birrer MJ, Moore KN, Spirtos NM, Shahin MS, Reid TJ, Friedlander M, Steffensen KD, Okamoto A, Sehgal V, Ansell PJ, Dinh MH, Bookman MA, Coleman RL. Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. Gynecol Oncol. 2022 Feb;164(2):245-253. doi: 10.1016/j.ygyno.2021.12.003. Epub 2021 Dec 11.
PubMed 34906376Washington CR, Moore KN. PARP inhibitors in the treatment of ovarian cancer: a review. Curr Opin Obstet Gynecol. 2021 Feb 1;33(1):1-6. doi: 10.1097/GCO.0000000000000675.
PubMed 33369580Nishikawa T, Matsumoto K, Tamura K, Yoshida H, Imai Y, Miyasaka A, Onoe T, Yamaguchi S, Shimizu C, Yonemori K, Shimoi T, Yunokawa M, Xiong H, Nuthalapati S, Hashiba H, Kiriyama T, Leahy T, Komarnitsky P, Fujiwara K. Phase 1 dose-escalation study of single-agent veliparib in Japanese patients with advanced solid tumors. Cancer Sci. 2017 Sep;108(9):1834-1842. doi: 10.1111/cas.13307. Epub 2017 Aug 5.
PubMed 28665051
Study at a glance
From the registry record, last updated by the sponsor on 26 Oct 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP Inhibitor) in Subjects With Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- ClinicalTrials.gov ID
- NCT02470585
- Acronym / sponsor ID
- VELIA / M13-694
- Conditions
- Ovarian Cancer, Ovarian Neoplasm
- Keywords
- Veliparib, Carboplatin, Paclitaxel, Overall Survival, ABT-888, Randomized, Poly Adenosine Diphosphate (ADP) - Ribose Polymerase (PARP), Ovarian
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Business decision not related to patient safety
- Enrolment
- 1,140 participants (actual)
- Lead sponsor
- AbbVieIndustry (pharma, biotech, devices)
- Collaborators
- Australia New Zealand Gynaecological Oncology Group
- Study start
- 14 Jul 2015 (actual)
- Primary completion
- 3 May 2019 (actual)
- Study completion
- 5 Oct 2023 (actual)
- First posted
- 12 Jun 2015 (estimated)
- Results
- Posted 14 Sep 2020
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective of the study was to evaluate whether progression-free survival (PFS) was prolonged with the addition of veliparib to standard platinum-based chemotherapy (carboplatin/paclitaxel [C/P]) and continued as maintenance therapy compared with chemotherapy alone.
Detailed description
Participants were randomized in a 1:1:1 ratio to one of three arms. Randomization in the entire population was stratified according to the timing of surgery and residual disease status (any residual disease after primary surgery vs. no residual disease after primary surgery vs. interval surgery) and the paclitaxel schedule (weekly vs. every 3 -weeks), stage of disease (III vs. IV), geographic region (Japan vs. North America and rest of world [ROW]), and germline breast cancer susceptibility gene (BRCA) mutation status (positive versus negative or Unknown).
Cytoreductive surgery could be performed before randomization and the initiation of study treatment (primary) or after 3 cycles of study treatment (interval). The weekly or every-3-week paclitaxel schedule and the choice of primary or interval cytoreductive surgery were determined at the discretion of the investigator.
The primary objective was evaluated in the BRCA-deficient cohort, participants with homologous recombination deficiency (HRD), and the intention-to-treat (ITT) population. These populations were sequentially inclusive, with the HRD population including the BRCA-deficient population, and the ITT population including the HRD and BRCA-deficient populations. The BRCA-deficient population was defined as participants with either a germline (gBRCA) and/or tissue-based (tBRCA) deleterious or suspected deleterious mutation in BRCA1 or BRCA2 confirmed by centralized testing. The HRD population was defined as participants with HRD tumors based on HRD score or presence of a deleterious or suspected deleterious mutation in BRCA1 or BRCA2 as determined by centralized testing.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Placebo + Carboplatin + Paclitaxel -> Placebo | Active comparator | Drug: Paclitaxel, Drug: Carboplatin, Other: Placebo to VeliparibParticipants will receive placebo to veliparib orally twice a day in combination with carboplatin/paclitaxel for six 21-day cycles followed by placebo monotherapy continuous dosing for an additional thirty 21-day cycles. |
| Veliparib + Carboplatin + Paclitaxel -> Placebo | Experimental | Drug: Veliparib, Drug: Paclitaxel, Drug: Carboplatin, Other: Placebo to VeliparibParticipants will receive 150 mg veliparib orally twice a day in combination with carboplatin/paclitaxel for six 21-day cycles followed by placebo monotherapy continuous dosing for an additional thirty 21-day cycles. |
| Veliparib + Carboplatin + Paclitaxel -> Veliparib | Experimental | Drug: Veliparib, Drug: Paclitaxel, Drug: CarboplatinParticipants will receive 150 mg veliparib orally twice a day in combination with carboplatin/paclitaxel for six 21-day cycles followed by 300/400 mg veliparib monotherapy orally twice a day for an additional thirty 21-day cycles. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Histologic diagnosis of International Federation of Gynecology and Obstetrics (FIGO) Stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, with the appropriate tissue available for histologic evaluation.
- High-grade serous adenocarcinoma
- Willing to undergo testing for gBRCA.
- Adequate hematologic, renal, and hepatic function.
- Neuropathy (sensory and motor) less than or equal to Grade 1.
Key exclusion criteria (8 listed)
- Endometrioid adenocarcinoma, carcinosarcoma, undifferentiated carcinoma, mixed epithelial adenocarcinoma, adenocarcinoma not otherwise specified, mucinous adenocarcinoma, clear cell adenocarcinoma, low-grade serous adenocarcinoma, or malignant Brenner's tumor.
- Participants with synchronous primary endometrial cancer, or a past history of endometrial cancer unless all of the following conditions are met: endometrial cancer stage not greater than IA, no vascular or lymphatic invasion, no poorly differentiated subtypes including serous, clear cell, or other FIGO grade 3 lesions.
- Participants with any evidence of other invasive malignancy being present within the last 3 years (with the exception of non-melanoma skin cancer). Participants are also excluded if their previous cancer treatment contraindicates this protocol's therapy.
- Received prior radiotherapy to any portion of the abdominal cavity or pelvis.
- Received prior chemotherapy for any abdominal or pelvic tumor.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| VeliparibAlso: ABT-888Capsules for oral administration | Drug | Veliparib + Carboplatin + Paclitaxel -> Placebo, Veliparib + Carboplatin + Paclitaxel -> Veliparib |
| PaclitaxelAdministered by intravenous infusion, either 80 mg/m² of body-surface area (BSA) on Days 1, 8, and 15 of each 21-day cycle (weekly dosing), or 175 mg/m² of BSA on Day 1 of each 21-day cycle (3-week dosing). | Drug | Placebo + Carboplatin + Paclitaxel -> Placebo, Veliparib + Carboplatin + Paclitaxel -> Placebo, Veliparib + Carboplatin + Paclitaxel -> Veliparib |
| CarboplatinAdministered by intravenous infusion at an area under the curve (AUC) of 6 mg/mL/min every 3 weeks. | Drug | Placebo + Carboplatin + Paclitaxel -> Placebo, Veliparib + Carboplatin + Paclitaxel -> Placebo, Veliparib + Carboplatin + Paclitaxel -> Veliparib |
| Placebo to VeliparibCapsules for oral administration | Other | Placebo + Carboplatin + Paclitaxel -> Placebo, Veliparib + Carboplatin + Paclitaxel -> Placebo |
Primary outcome
Progression-Free Survival (PFS) in the BRCA-deficient Population (Arm 3 vs Arm 1)
Time frame: From randomization until the primary analysis data cut-off date of 03 May 2019, the median duration of follow-up was 28 months.
PFS was defined as the time from the date that the participant was randomized to the date the participant experienced an event of disease progression, according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1 (as determined by the investigator) or to the date of death if disease progression was not reached. If the participant did not have an event of disease progression or death prior to the analysis cut-off date, the participant's data were censored at the date of their last evaluable disease assessment. PFS was estimated using the Kaplan-Meier method. The analysis of PFS occurred when the protocol-specified number of PFS events was reached. Progressive Disease (PD): At least a 20% increase in the size of target lesions, compared with the smallest size recorded since the treatment started, and an absolute increase of ≥ 5 mm, or unequivocal progression of existing non-target lesions or the appearance of new lesions.
Progression-Free Survival (PFS) in the Homologous Recombination Deficiency Cohort (Arm 3 vs Arm 1)
Time frame: From randomization until the primary analysis data cut-off date of 03 May 2019, the median duration of follow-up was 28 months.
PFS was defined as the time from the date that the participant was randomized to the date the participant experienced an event of disease progression, according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1 (as determined by the investigator) or to the date of death if disease progression was not reached. If the participant did not have an event of disease progression or death, the participant's data were censored at the date of their last evaluable disease assessment. PFS was estimated using the Kaplan-Meier method. The primary analysis of PFS occurred when the protocol-specified number of PFS events was reached and was performed in 3 sequentially inclusive populations. Progressive Disease (PD): At least a 20% increase in the size of target lesions, compared with the smallest size recorded since the treatment started, and an absolute increase of ≥ 5 mm, or unequivocal progression of existing non-target lesions or the appearance of new lesions. .
Progression-Free Survival (PFS) in the Intention-to-treat Population (Arm 3 vs Arm 1)
Time frame: From randomization until the primary analysis data cut-off date of 03 May 2019, the median duration of follow-up was 28 months.
PFS was defined as the time from the date that the participant was randomized to the date the participant experienced an event of disease progression, according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1 (as determined by the investigator) or to the date of death (all causes of mortality) if disease progression was not reached. If the participant did not have an event of disease progression according to RECIST criteria (as or death, the participant's data were censored at the date of their last evaluable disease assessment. PFS was estimated using the Kaplan-Meier method. Progressive Disease (PD): At least a 20% increase in the size of target lesions, compared with the smallest size recorded since the treatment started, and an absolute increase of ≥ 5 mm, or unequivocal progression of existing non-target lesions or the appearance of new lesions. The primary analysis of PFS occurred when the protocol-specified number of PFS events was reached.
9 secondary outcomes
Progression-Free Survival (PFS) in the BRCA-deficient Population (Arm 2 vs Arm 1)
Time frame: From randomization until the primary analysis data cut-off date of 03 May 2019, the median duration of follow-up was 28 months.
Progression-Free Survival (PFS) in the Homologous Recombination Deficiency Cohort (Arm 2 vs Arm 1)
Time frame: From randomization until the primary analysis data cut-off date of 03 May 2019, the median duration of follow-up was 28 months.
Progression-Free Survival (PFS) in the Intention-to-treat Population (Arm 2 vs Arm 1)
Time frame: From randomization until the primary analysis data cut-off date of 03 May 2019, the median duration of follow-up was 28 months.
Overall Survival (OS) in the BRCA-deficient Population
Time frame: From the time of randomization to the end of the study, up to 98 months
Overall Survival (OS) in the Homologous Recombination Deficiency Population
Time frame: From the time of randomization to the end of the study, up to 98 months
Overall Survival (OS) in the Whole Population
Time frame: From the time of randomization to the end of the study, up to 98 months
Change From Baseline in Disease Related Symptom (DRS) Score in the BRCA-mutation Population
Time frame: Baseline and Day 1 of Cycles 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, and 35
Change From Baseline in Disease Related Symptom (DRS) Score in the HRD Population
Time frame: Baseline and Day 1 of Cycles 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, and 35
Change From Baseline in Disease Related Symptom (DRS) Score in the Whole Population
Time frame: Baseline and Day 1 of Cycles 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, and 35
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Oct 2024.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Background: PubMed 31562800Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Efrat Ben-Baruch N, Werner TL, Cloven NG, Oaknin A, DiSilvestro PA, Morgan MA, Nam JH, Leath CA 3rd, Nicum S, Hagemann AR, Littell RD, Cella D, Baron-Hay S, Garcia-Donas J, Mizuno M, Bell-McGuinn K, Sullivan DM, Bach BA, Bhattacharya S, Ratajczak CK, Ansell PJ, Dinh MH, Aghajanian C, Bookman MA. Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. N Engl J Med. 2019 Dec 19;381(25):2403-2415. doi: 10.1056/NEJMoa1909707. Epub 2019 Sep 28.
- Derived from this study: PubMed 41565553Lafferty J, Secord AA, Bookman M, Coleman RL, Dinh MH, Khandelwal N, Kamalakar R, Cella D. Quality-adjusted progression-free survival analysis of veliparib and carboplatin/paclitaxel compared with chemotherapy alone in patients with newly diagnosed ovarian cancer (VELIA/GOG3005): ancillary analysis of a placebo-controlled, phase 3 randomized trial. Int J Gynecol Cancer. 2026 May;36(5):102819. doi: 10.1016/j.ijgc.2025.102819. Epub 2025 Nov 21.
- Derived from this study: PubMed 34906376Swisher EM, Aghajanian C, O'Malley DM, Fleming GF, Kaufmann SH, Levine DA, Birrer MJ, Moore KN, Spirtos NM, Shahin MS, Reid TJ, Friedlander M, Steffensen KD, Okamoto A, Sehgal V, Ansell PJ, Dinh MH, Bookman MA, Coleman RL. Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. Gynecol Oncol. 2022 Feb;164(2):245-253. doi: 10.1016/j.ygyno.2021.12.003. Epub 2021 Dec 11.
- Derived from this study: PubMed 33369580Washington CR, Moore KN. PARP inhibitors in the treatment of ovarian cancer: a review. Curr Opin Obstet Gynecol. 2021 Feb 1;33(1):1-6. doi: 10.1097/GCO.0000000000000675.
- Derived from this study: PubMed 28665051Nishikawa T, Matsumoto K, Tamura K, Yoshida H, Imai Y, Miyasaka A, Onoe T, Yamaguchi S, Shimizu C, Yonemori K, Shimoi T, Yunokawa M, Xiong H, Nuthalapati S, Hashiba H, Kiriyama T, Leahy T, Komarnitsky P, Fujiwara K. Phase 1 dose-escalation study of single-agent veliparib in Japanese patients with advanced solid tumors. Cancer Sci. 2017 Sep;108(9):1834-1842. doi: 10.1111/cas.13307. Epub 2017 Aug 5.
- Individual participant dataSharing planned: Yes. AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Related trials for Ovarian Cancer
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Recruiting
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Ovarian Carcinoma
RecruitingPhase 2
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Ovarian Cancer, Fallopian Tube Cancer
Active, not recruitingPhase 1/2
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
Colorectal Neoplasms, Breast Neoplasms
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
AbbVie Inc. study director
AbbVie
210 sites in 11 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Veliparib, Paclitaxel and Carboplatin in people with Ovarian Cancer and Ovarian Neoplasm, run by AbbVie at 210 sites in 11 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 26 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 210 sites in United States, Japan, Australia, Spain, Israel and 6 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 14 Sep 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Progression-Free Survival (PFS) in the BRCA-deficient Population (Arm 3 vs Arm 1) (time frame: From randomization until the primary analysis data cut-off date of 03 May 2019, the median duration of follow-up was 28 months.). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02470585, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Oct 2024.